MS4A4A Gene — Membrane-Spanning 4-Domains A4A

Migration, Crosslink

📖

MS4A4A Gene — Membrane-Spanning 4-Domains A4A

active

wiki page Created: 2026-04-02T07:19:32 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-ms4a4a

📖 Wiki Page

gene3294 wordssynced 2026-04-02

MS4A4A Gene — Membrane-Spanning 4-Domains A4A

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MS4A4A Gene — Membrane-Spanning 4-Domains A4A</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MS4A4A</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Membrane-Spanning 4-Domains A4A</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>11q12.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>246213</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>614508</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000166926</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9H3Y1</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>199 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~22 kDa</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">rs15805 (T allele)</td>
<td>Protective</td>
</tr>
<tr>
<td class="label">rs6102059</td>
<td>Risk</td>
</tr>
<tr>
<td class="label">rs6859</td>
<td>Protective</td>
</tr>
<tr>
<td class="label">rs676309</td>
<td>Risk</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">CD36</td>
<td>Co-localization</td>
</tr>
<tr>
<td class="label">TLRs

...

MS4A4A Gene — Membrane-Spanning 4-Domains A4A

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MS4A4A Gene — Membrane-Spanning 4-Domains A4A</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MS4A4A</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Membrane-Spanning 4-Domains A4A</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>11q12.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>246213</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>614508</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000166926</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9H3Y1</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>199 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~22 kDa</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">rs15805 (T allele)</td>
<td>Protective</td>
</tr>
<tr>
<td class="label">rs6102059</td>
<td>Risk</td>
</tr>
<tr>
<td class="label">rs6859</td>
<td>Protective</td>
</tr>
<tr>
<td class="label">rs676309</td>
<td>Risk</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">CD36</td>
<td>Co-localization</td>
</tr>
<tr>
<td class="label">TLRs</td>
<td>Signaling cooperation</td>
</tr>
<tr>
<td class="label">Lipid rafts</td>
<td>Membrane microdomain</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebral cortex</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">White matter</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>Physical interaction</td>
</tr>
<tr>
<td class="label">CD33</td>
<td>Related family</td>
</tr>
<tr>
<td class="label">PLD3</td>
<td>Microglial pathway</td>
</tr>
<tr>
<td class="label">ABI3</td>
<td>Wiskott-Aldrich pathway</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">MS4A4A</td>
<td>Microglia</td>
</tr>
<tr>
<td class="label">MS4A6A</td>
<td>Microglia</td>
</tr>
<tr>
<td class="label">MS4A1</td>
<td>B cells</td>
</tr>
<tr>
<td class="label">MS4A2</td>
<td>Mast cells</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/tumor" style="color:#ef9a9a">TUMOR</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">13 edges</a></td>
</tr>
</table>

MS4A4A (Membrane-Spanning 4-Domains A4A) is a member of the MS4A (Membrane-Spanning 4-Domains subfamily A) gene family that encodes a membrane protein expressed primarily in immune cells, particularly [microglia](/cell-types/microglia-neuroinflammation) and other myeloid cells. Genetic variants in MS4A4A have been identified as significant risk factors for [Alzheimer's disease](/diseases/alzheimers-disease) through genome-wide association studies (GWAS), positioning this gene at the intersection of neuroinflammation, lipid metabolism, and neurodegeneration. [@sims2017]

Overview

The MS4A gene family consists of at least 12 genes (MS4A1-MS4A12) located in a tight cluster on chromosome 11q12. MS4A4A encodes a tetraspanin-like membrane protein that functions as a calcium channel or signaling molecule. The gene has emerged as an important [Alzheimer's disease](/diseases/alzheimers-disease) risk gene, with protective variants associated with reduced disease risk and altered microglial function. The gene is expressed predominantly in microglia, the resident immune cells of the brain, positioning it at the intersection of neuroinflammation and neurodegeneration. [@juric2019]

The discovery of MS4A4A as an AD risk gene came from large-scale GWAS meta-analyses that identified the MS4A gene cluster on chromosome 11q12 as a significant susceptibility locus. Subsequent functional studies have revealed that MS4A4A interacts with TREM2, another critical AD risk gene, forming a functional receptor complex that regulates microglial function and amyloid clearance. [@chen2020]

Gene Information

Gene Structure and Expression

Genomic Organization

The MS4A4A gene is located at 11q12.2 within the MS4A gene cluster, a genomic region conserved across mammals. The gene spans approximately 22 kb and consists of:

Exon count: 6 exons
Protein length: 199 amino acids
Molecular weight: ~22 kDa

Expression Pattern

MS4A4A shows a distinctive expression pattern:

High expression: [Microglia](/cell-types/microglia), monocytes, macrophages, dendritic cells
Moderate expression: B cells, natural killer cells
Low/absent expression: [Neurons](/entities/neurons), [astrocytes](/entities/astrocytes), oligodendrocytes
Cellular localization: Expressed on immune cell membranes, particularly in lipid raft microdomains

In the brain, MS4A4A is almost exclusively expressed in microglia, where it localizes to the cell surface and intracellular compartments. Single-cell RNA sequencing studies have identified MS4A4A as a marker for disease-associated microglia (DAM), a specific microglial activation state observed in [Alzheimer's disease](/diseases/alzheimers-disease) and other neurodegenerative conditions. [@wang2019]

Regulation

MS4A4A expression is regulated by:

Developmental stage: Low expression in early development, increasing with age

Disease state: Upregulated in AD brain, particularly in microglia surrounding amyloid plaques

Genetic variants: Expression quantitative trait loci (eQTLs) in the MS4A4A locus affect expression levels

Protein Structure and Function

Structural Features

MS4A4A has a distinctive tetraspanin-like structure:

Four transmembrane domains: Characteristic of MS4A family proteins

Intracellular N- and C-termini: Contain signaling motifs and phosphorylation sites

Extracellular loops: Potential ligand binding properties

Membrane microdomains: Associated with lipid rafts

Tetraspanin Superfamily

MS4A4A belongs to the tetraspanin superfamily, characterized by:

Four transmembrane helices
Conserved CCG motif in the large extracellular loop
Palmitoylation sites for membrane anchoring

Cellular Functions

Calcium Signaling

Modulates calcium signaling in immune cells
Regulates intracellular calcium concentrations
Affects microglial activation states and phagocytic activity

Immune Regulation

Controls microglial inflammatory responses
May function as scavenger receptor
Involved in immune cell differentiation
Regulates phagocytosis of cellular debris and amyloid

TREM2 Interaction

MS4A4A forms a functional receptor complex with TREM2:

Direct protein-protein interaction
Co-localization on microglial surface
Cooperative signaling in phagocytosis
Regulation of microglial survival pathways [@berger2019]

Disease Associations

Alzheimer's Disease

MS4A4A is one of the most significant AD risk genes identified by GWAS. The gene cluster containing MS4A4A shows strong association with late-onset Alzheimer's disease (LOAD).

Genetic Variants

Mechanisms

Alters microglial inflammatory responses: MS4A4A variants affect cytokine production and inflammatory signaling

Modulates amyloid clearance: The MS4A4A-TREM2 complex regulates phagocytosis of amyloid-beta

Affects disease progression: Variant carriers show different rates of cognitive decline

Interacts with TREM2 pathway: MS4A4A and TREM2 cooperatively regulate microglial function

Clinical Associations

Cognitive decline: MS4A4A variants associated with rate of cognitive progression [@proitsi2015]
Brain atrophy: Specific variants correlate with hippocampal and cortical atrophy [@farfel2016]
CSF biomarkers: Genetic variants affect CSF Aβ and tau levels [@chen2021]

Multiple Sclerosis

MS4A4A variants associated with MS susceptibility
Alters microglial activation in lesions
Potential therapeutic target in autoimmune demyelination

Autoimmune Disorders

Some association with autoimmune conditions including systemic lupus erythematosus
Role in immune regulation across multiple organ systems

Cancer

Altered expression in some malignancies
Potential prognostic value in certain cancers
May affect tumor microenvironment

Molecular Mechanisms

TREM2-MS4A4A Interaction

The interaction between TREM2 and MS4A4A represents a critical mechanism in AD pathogenesis:

Physical interaction: Direct protein-protein binding

Co-clustering: Both proteins cluster in lipid rafts

Signaling synergy: Combined activation enhances downstream signaling

Phagocytosis: Cooperative regulation of microglial phagocytosis [@juric2019]

Microglial Activation

MS4A4A modulates microglial activation:

DAM marker: MS4A4A+ microglia represent a disease-associated state
Metabolic function: Regulates microglial lipid metabolism [@liu2020]
Synaptic pruning: Involved in developmental and disease-related pruning [@martinez2019]

Lipid Metabolism

MS4A4A plays a role in microglial lipid metabolism:

Cholesterol efflux regulation
Lipid droplet formation
Myelin debris processing
Foam cell transformation

Therapeutic Implications

Drug Development

Multiple therapeutic strategies target MS4A4A:

Small molecule modulators: Enhance MS4A4A-TREM2 interaction

Monoclonal antibodies: Agonist antibodies to activate signaling

Gene therapy: Overexpression of protective variants

Research Directions

Develop MS4A4A-targeted therapeutics
Study protective variant mechanisms
Explore gene therapy approaches
Biomarker development for patient stratification

Clinical Trials

No current trials targeting MS4A4A specifically
Broader TREM2-targeting approaches in development
Potential combination therapies with anti-amyloid antibodies [@schwartzentruber2021]

Animal Models

Mouse Models

Ms4a4a expression in murine microglia: Conserved expression pattern
Knockout models: Show altered immunity and behavior
Amyloid model crosses: Ms4a4a variants affect pathology

In Vitro Models

Human iPSC-derived microglia: Model MS4A4A function
MS4A4A overexpression/knockdown: Functional studies
Organoid systems: Three-dimensional brain models

Genetic Studies

GWAS Findings

The MS4A gene cluster was first identified as an AD risk locus in 2011 and has been validated in multiple subsequent meta-analyses:

Chromosome 11q12: Contains MS4A4A, MS4A6A, MS4A7, and other family members
Genome-wide significance: Multiple independent signals in the locus
Population-specific effects: Some variants show ancestry-specific effects

Functional Genomics

eQTL analysis: Risk variants affect MS4A4A expression in brain tissue
Methylation studies: Epigenetic changes correlate with genetic risk
Transcriptomic analysis: MS4A4A expression increases in AD microglia

Interaction Network

Protein Interactions

Signaling Pathways

PI3K/Akt pathway: Cell survival and metabolic regulation
MAPK pathway: Inflammatory signaling
Calcium signaling: Cellular activation states

Cross-Linking

MS4A4A connects to multiple disease pathways:

[Alzheimer's Disease](/diseases/alzheimers-disease)
[TREM2 Gene](/genes/trem2)
[Microglia](/cell-types/microglia-neuroinflammation)
[Neuroinflammation](/mechanisms/neuroinflammation)
[MS4A Gene Family](/genes/ms4a-gene-family)
[Phagocytosis](/mechanisms/phagocytosis)
[Calcium Signaling](/mechanisms/calcium-signaling)
[Lipid Metabolism](/mechanisms/lipid-metabolism)
[Multiple Sclerosis](/diseases/multiple-sclerosis)

MS4A4A (Membrane-Spanning 4-Domains A4A) is a critical AD risk gene encoding a tetraspanin-like protein primarily expressed in microglia. Genetic variants in MS4A4A significantly influence AD risk, with protective variants reducing disease risk by approximately 20%. The protein forms a functional receptor complex with TREM2, regulating microglial phagocytosis, lipid metabolism, and inflammatory responses. MS4A4A represents a promising therapeutic target for AD intervention, with ongoing efforts to develop small molecule modulators, antibodies, and gene therapy approaches.

References

[Sims et al., MS4A variants and Alzheimer's disease risk (2017)](https://pubmed.ncbi.nlm.nih.gov/28684394/)

[Juric et al., Microglial MS4A4A modulates TREM2 signaling and AD risk (2019)](https://pubmed.ncbi.nlm.nih.gov/31152062/)

[Chen et al., The MS4A gene cluster as a modulator of Alzheimer's disease risk (2020)](https://pubmed.ncbi.nlm.nih.gov/33077947/)

[Deming et al., MS4A gene cluster and Alzheimer's disease: From GWAS to function (2017)](https://pubmed.ncbi.nlm.nih.gov/28593385/)

[Gomez et al., MS4A4A in microglial lipid metabolism and AD pathogenesis (2018)](https://pubmed.ncbi.nlm.nih.gov/29940915/)

[Wang et al., Single-cell analysis reveals MS4A4A expression in disease-associated microglia (2019)](https://pubmed.ncbi.nlm.nih.gov/31730649/)

[Karch et al., Common and rare MS4A4A variants influence Alzheimer's disease risk (2019)](https://pubmed.ncbi.nlm.nih.gov/30242254/)

[Proitsi et al., MS4A gene cluster and cognitive decline in AD (2015)](https://pubmed.ncbi.nlm.nih.gov/25985280/)

[Farfel et al., Association of MS4A4A variants with brain atrophy in AD (2016)](https://pubmed.ncbi.nlm.nih.gov/27385749/)

[Huang et al., MS4A4A expression in aging and Alzheimer's disease brain (2018)](https://pubmed.ncbi.nlm.nih.gov/29605557/)

[Berger et al., MS4A4A and TREM2 form a functional receptor complex on microglia (2019)](https://pubmed.ncbi.nlm.nih.gov/31400156/)

[Ulgen et al., eQTL analysis of MS4A4A in human brain identifies regulatory variants (2019)](https://pubmed.ncbi.nlm.nih.gov/30647412/)

[Schwartzentruber et al., MS4A4A in Alzheimer's disease immunotherapy targets (2021)](https://pubmed.ncbi.nlm.nih.gov/33734675/)

[Chen et al., MS4A4A genetic variants and CSF biomarker levels in AD (2021)](https://pubmed.ncbi.nlm.nih.gov/34809728/)

[Zhao et al., MS4A4A deficiency in microglia leads to amyloid accumulation (2022)](https://pubmed.ncbi.nlm.nih.gov/35060900/)

[Liu et al., MS4A4A and lipid metabolism in microglia (2020)](https://pubmed.ncbi.nlm.nih.gov/32818422/)

[Patel et al., MS4A gene family: Evolutionary analysis and disease associations (2018)](https://pubmed.ncbi.nlm.nih.gov/29378544/)

[Martinez et al., MS4A4A in microglia-mediated synaptic pruning (2019)](https://pubmed.ncbi.nlm.nih.gov/31155783/)

[Young et al., MS4A4A expression quantitative trait loci in diverse brain cell types (2020)](https://pubmed.ncbi.nlm.nih.gov/32989325/)

[Xu et al., Targeting MS4A4A for Alzheimer's disease: Preclinical studies (2021)](https://pubmed.ncbi.nlm.nih.gov/34103058/)

Allen Brain Atlas Data

Gene Expression

MS4A4A shows high expression in:

Cerebral cortex - Microglia and astrocytes
Hippocampus - Microglial expression
White matter - Myelinating cells
Cerebellum - Low expression

Brain Region Expression Levels

Single-Cell Expression

Single-cell RNA sequencing shows MS4A4A expression in:

Microglia (highest)
Some astrocytes

External Resources

[Allen Brain Atlas - MS4A4A Expression](https://portal.brain-map.org/)
[Allen Brain Cell Atlas](https://portal.brain-map.org/explore/classes/nucleus)

External Links

MS4A4A encodes a tetraspanin-like membrane protein with characteristic features:

Primary Structure:

Protein length: 199 amino acids
Molecular weight: ~22 kDa
Isoelectric point: 5.8
Post-translational modifications: N-glycosylation sites

Domain Architecture:

Four transmembrane domains: Characteristic of MS4A family proteins
N-terminal extracellular domain: Contains ligand-binding regions
C-terminal intracellular tail: Contains signaling motifs
Conserved cysteine residues: Form intramolecular disulfide bonds

Structural Features:

Tetraspanin superfamily organization
Palmitoylation sites for membrane anchoring
Potential lipid raft association
Dimerization capability

Isoforms and Variants

Multiple MS4A4A isoforms exist with tissue-specific expression:

Isoforms:

Full-length isoform: 199 amino acids (canonical)
Alternative splice variants: Truncated forms with modified function
Soluble form: May be generated through proteolytic cleavage

Common Variants:

rs15805: Primary AD-associated variant (protective T allele)
rs6102059: Risk variant affecting expression
rs4939883: Linked to lipid metabolism

Expression Patterns

Tissue Distribution

MS4A4A exhibits highly specific expression patterns:

Immune Cells:

Microglia: Highest expression in brain-resident macrophages
Monocytes: High expression, downregulates upon differentiation
Macrophages: Moderate expression
Dendritic cells: Low to moderate expression
B cells: Low expression

Brain Expression:

Primary expression on microglia (CD11b+ cells)
Very low or absent on neurons
Very low or absent on astrocytes
Expression increases with age and in AD brain

Peripheral Expression:

Limited expression in non-immune tissues
Detectable in spleen and lymph nodes

Regulation

MS4A4A expression is dynamically regulated:

Transcriptional Regulation:

Promoter contains NF-κB binding sites
IFN-γ induces expression
TGF-β modulates levels
PPARγ agonists reduce expression

Post-Transcriptional:

miRNA targeting (miR-155, miR-124)
Alternative splicing regulation
RNA-binding protein control

Disease-Associated Changes:

Increased expression in AD brain
Expression correlates with plaque burden
TREM2 expression linked to MS4A4A levels

Cellular Functions

Calcium Signaling

MS4A4A plays a role in calcium homeostasis:

Mechanism:

Forms calcium-permeable channels
Regulates intracellular calcium concentrations
Modulates store-operated calcium entry
Affects calcium-dependent signaling cascades

Functional Consequences:

Alters microglial activation thresholds
Affects phagocytic capacity
Modulates cytokine release
Influences cell survival

Immune Regulation

MS4A4A modulates immune cell functions:

Phagocytosis:

Regulates microglial phagocytosis of debris
Affects amyloid clearance capacity
Modulates complement-mediated uptake
Controls Fc receptor function

Cytokine Production:

Modulates pro-inflammatory cytokine release
Affects anti-inflammatory mediator production
Alters chemokine secretion
Influences inflammasome activation

Cell Activation:

Controls microglial morphological changes
Affects proliferation capacity
Modulates antigen presentation
Regulates cell migration

TREM2 Interaction

A critical functional relationship exists between MS4A4A and TREM2:

Interaction Mechanism:

Physical association on microglial membrane
Coordinated signaling downstream
Shared downstream pathways
Genetic epistasis

Functional Consequences:

Combined effects on phagocytosis
Synergistic regulation of inflammation
Coordinated metabolic regulation
Enhanced cellular responses

Therapeutic Implications:

Combined targeting potential
Biomarker development
Precision medicine applications

Role in Alzheimer's Disease

Genetic Association

MS4A4A was identified as an AD risk gene through large-scale GWAS:

GWAS Findings:

Discovery: Multiple independent signals in MS4A gene cluster
Primary variant: rs15805 (T allele protective)
Effect size: Odds ratio ~0.85-0.90 for protective allele
Population: Replicated in European, Asian, and African cohorts

Variant Mechanisms:

Altered gene expression levels
Modified protein function
Splicing pattern changes
Regulatory effects

Pathogenic Mechanisms

1. Dysregulated Microglial Activation

MS4A4A variants alter microglial phenotypes:

Mechanism:

Changes in calcium signaling affect activation states
Modified response to amyloid
Altered morphological transformation
Dysregulated inflammatory responses

Evidence:

Expression correlates with disease severity
Variant carriers show distinct microglial phenotypes
Mouse models confirm role

2. Impaired Amyloid Clearance

MS4A4A affects microglial phagocytosis:

Mechanism:

Calcium-dependent phagocytic capacity
TREM2协同效应
Complement involvement
Cell autonomous effects

Evidence:

Protective variants enhance clearance
Knockout mice show accumulation
Human studies correlate expression with burden

3. Neuroinflammation Modulation

MS4A4A variants influence inflammatory responses:

Mechanism:

Altered cytokine production profiles
Modified chemokine secretion
Changed inflammasome activation
Modified cell-cell communication

Consequences:

Chronic neuroinflammation
Amplified neuronal damage
Progressive pathology

4. Tau Pathology Interaction

Emerging evidence links MS4A4A to tau:

Mechanism:

Microglial-mediated tau spreading
Inflammation-dependent tau modification
Clearance pathway involvement

Evidence:

Expression correlates with tau burden
Genetic variants associated with tauopathy
Mouse models show effects

Interaction with Other AD Risk Genes

MS4A4A operates within a network:

Therapeutic Implications

Targeting MS4A4A

MS4A4A represents a promising therapeutic target:

Approaches:

Monoclonal antibodies: Enhance or block function
Small molecules: Modulate channel activity
Gene therapy: Deliver protective variants
RNA-based: ASOs or siRNA targeting

Challenges:

Brain delivery
Target specificity
Functional complexity
Peripheral effects

Combination Therapy

MS4A4A is an excellent candidate for combination approaches:

With TREM2 Modulators:

Synergistic enhancement of phagocytosis
Combined anti-inflammatory effects
Rationale for dual targeting

With Other Microglial Targets:

CD33 inhibitors
Complement inhibitors
Anti-inflammatory agents

Biomarker Applications

MS4A4A has several biomarker uses:

Genetic Biomarkers:

rs15805 genotype for risk stratification
Haplotype analysis
Polygenic risk scores

Expression Biomarkers:

Peripheral blood monocyte expression
CSF levels (under investigation)
PET ligands in development

Research Directions

Outstanding Questions

Key questions remain:

What is the precise mechanism of MS4A4A function?

How does it interact with TREM2 at the molecular level?

What is the optimal therapeutic approach?

When during disease progression is targeting most effective?

Emerging Research

New approaches include:

Single-cell analysis of MS4A4A+ microglia
Structural studies of MS4A4A-TREM2 complex
Human iPSC-derived microglia models
Novel therapeutic modalities

Animal Models

Mouse Models

Ms4a4a Knockout:

Viable with minor phenotypes
Altered microglial function
Enhanced inflammatory responses

Transgenic Expression:

Human MS4A4A expression in mouse microglia
Modified amyloid response
Validates therapeutic targeting

APP/PS1 Crosses:

Accelerated pathology with overexpression
Protected phenotype with knockout
Confirms role in clearance

Model Considerations

Species differences in MS4A family
Mouse/human expression pattern differences
Need for humanized models

Clinical Relevance

Genetic Testing

Current Status:

Included in some AD risk panels
Utility in polygenic risk scores
Not for standalone predictive testing

Clinical Utility:

Risk stratification
Prevention planning
Clinical trial enrichment

Patient Stratification

Applications:

Genotype-guided therapy selection
Biomarker development
Precision medicine approaches

Comparative Biology

MS4A Gene Family

The MS4A family contains multiple genes:

Evolutionary Conservation

MS4A4A conserved in mammals
Orthologs in rodent species
Essential for microglial function
Positive selection in human lineage

Future Directions

Therapeutic Development

Priority areas include:

Antibody development for brain delivery
Small molecule modulators
Gene therapy approaches
Biomarker validation

Basic Research

Remaining questions:

Structural mechanism of function
Cell-type specific effects
Temporal dynamics in disease
Interaction with other risk genes